APP Pharmaceuticals Announces Approval of Levothyroxine Sodium for Injection

APP Pharmaceuticals announced that it has received approval from the FDA for Levothyroxine Sodium for Injection. Levothyroxine Sodium for Injection is indicated for the treatment of myxedema coma, a life-threatening complication of hypothyroidism.
Business Wire